Illumigen Biosciences is dedicated to the ethical application of genetic and information technologies to cure disease and improve the quality of human life. To this end we are applying our Protective Polymorphismâ„¢ technologies to revolutionizing the discovery and development of drugs and the practice of medicine. (Acquired by Cubist, now a division of Merck)